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ABSTRACT
Objectives Methotrexate (MTX) is currently the
recommended first-line therapy for treating psoriatic
arthritis (PsA), despite lacking clear evidence. No estimates
of efficacy of MTX in usual care and no clear MTX responsive
clinical or laboratory variables are currently available. This
study describes the response to MTX monotherapy in newly
diagnosed patients with PsA in usual care. Second, we
compared clinical variables and cytokine profiles in patients
responding and not responding to MTX monotherapy.
Methods We used data collected in the Dutch southwest
Early Psoriatic Arthritis cohoRt study to select patients with
PsA with oligoarthritis or polyarthritis, and at least 1 year
follow-up. We analysed disease activity at 6 months of
patients who started MTX monotherapy and still used MTX
monotherapy 1 year after diagnosis. Cytokine profiles were
determined at baseline and after 3 and 6 months with
a bead-based multi-immunoassay.
Results We identified 219 patients of which 183 (84%)
patients started MTX monotherapy within 6 months after
diagnosis. 90 patients used MTX monotherapy throughout
the first year of which 44 patients (24%) reached minimal
disease activity(MDA) at 6 months, decreasing to 33
patients (18%) after 1 year. Non-responders had
significantly higher concentrations of interleukin (IL) 23 and
IL-10 before and during MTX therapy.
Conclusions Our results showed that only 18% of patients
with PsA are in sustained MDA after 1 year of MTX
monotherapy and non-responders more often had IL-23-
driven disease. Our results indicate the need for more treat-
to-target and personalised therapy strategies in PsA.
INTRODUCTION
Psoriatic arthritis (PsA) is a musculoskeletal
disease associated with psoriasis presenting
with any or all of peripheral arthritis, axial
disease, dactylitis, enthesitis, in addition to
skin and nail disease. Inadequately treated,
PsA can lead to progressive joint damage and
disability. Both current EULAR andGroup for
Research and Assessment of Psoriasis and
Psoriatic Arthritis guidelines advise metho-
trexate (MTX) as first-line therapy for PsA,1 2
despite lacking clear evidence, but due to
positive expert experience and limitations of
available studies.
Until now, the only randomised controlled
trial, the Methotrexate in Psoriatic Arthritis
(MIPA) trial,3 found no significant effect of
MTX monotherapy on several response cri-
teria. However, the MIPA trial did not use the
optimal doses of MTX, and its results, there-
fore, are heavily debated. Furthermore, in the
TIght COntrol of inflammation in Psoriatic
Arthritis (TICOPA) trial, which compared
standard care with treat-to-target therapy stra-
tegies for PsA,4 only 22.4% of the patients
achieved minimal disease activity (MDA) after
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Key messages
What is already known about this subject?
► MTX is recommended as first-line therapy for
articular disease in most PsA treatment guidelines,
due to positive expert experience and limitations of
available studies demonstrating a lack of significant
effect of MTX therapy.
What does this study add?
► Only 18% of all patients reach sustained MDA on
MTX monotherapy alone in the first year after their
diagnosis.
► Patients not responding to MTX monotherapy have
high levels of IL-23, which are not lowered by
therapy with MTX.
How might this impact on clinical practice?
► Personalised therapy strategies are needed in PsA
because of the clinical and immunological
heterogeneity of disease activity and treatment
response.
► IL-23 might serve as therapy-response biomarker.
Psoriatic arthritis
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12 weeks of MTX monotherapy.5 Multiple studies have
used MTX monotherapy in their control-arm in rando-
mised controlled trials for tumour necrosis factor inhibitor
(TNFi) therapy in PsA or have investigated the MTX
response in an observational cohort, with a percentage of
patients reachingMDA varying from18% to 29%.6–8 Based
on the abovementioned trials, the new American College
of Rheumatology/National Psoriasis Foundation guide-
lines recommend the use of TNFi before MTX9 but still
classify the evidence as low.9
The advantages of MTX in usual care as compared to
TNFi are the worldwide availability, the known safety
profile and low costs. However, if a large proportion of
patients with PsA will not respond to MTX therapy,
understanding why and which patients will not respond
before start of therapy is needed. Due to the heteroge-
neous nature of PsA, it might be difficult to identify these
patients based on clinical variables alone and adding
laboratory variables predictive of MTX response could
prove to be valuable.
The current study aims to describe the response to
MTXmonotherapy early in the disease course of patients
with PsA with oligoarthritis or polyarthritis. Second, we
aimed to compare cytokine profiles in patients respond-
ing and not responding to MTX monotherapy to deter-
mine variables that can serve as easy-to-measure therapy-
response biomarkers.
METHODS
Patients, setting and patient involvement
We used data collected in the Dutch southwest Early Psor-
iatic Arthritis cohoRt (DEPAR) study, of which details are
described elsewhere.10 In short, DEPAR collects data to
investigate the daily clinical practice of patients with PsA.
Patients with a new diagnosis of PsA are eligible to partici-
pate if they did not yet receive treatment with disease-
modifying antirheumatic drugs (DMARDs) for PsA before
the first study visit. Use of DMARDs prescribed for psoriasis
was allowed. The baseline visit takes place as soon as pos-
sible after diagnosis, within a few weeks. Written informed
consent was obtained from all participants according to
theDeclaration ofHelsinki. The study was approved by the
local medical research ethics committee of Erasmus Med-
ical Centre Rotterdam, the Netherlands (MEC-2012-549).
During the feasibility stage, the research questions and the
choice for patient-related outcome measures were
informed by discussions with patients. For this analysis,
we used data collected between August 2013 and
April 2018, of patients with a phenotype of oligoarthritis
(2–4 joints involved) or polyarthritis (5 or more joints
involved) at baseline as defined by the treating rheumatol-
ogist, and at least 1 year follow-up.
Data collection
Clinical data and blood samples were collected every 3
months in the first year after diagnosis. Trained research
nurses collected data of medication use and clinical data,
including swollen and tender joint count (SJC 66 and TJC
68 joints, respectively), enthesitis at clinical examination
(Leeds Enthesitis Index,11 LEI), dactylitis count, physi-
cian global Visual Analogue Scale (VAS) and psoriasis
(Psoriasis Area and Severity Index,12 PASI). Patients filled
out questionnaires shortly before or after their visit to the
research nurse. In DEPAR, multiple questionnaires are
collected to measure the patient-reported activity of the
disease and different outcomes. For the current study, we
used self-reported symptom duration before diagnosis,
the Health Assessment Questionnaire (HAQ), patient
global VAS and patient pain VAS. For the patient global
VAS, patients were asked howmuch their life was affected
by their PsA.13
MTX response
In patients with a subtype of oligoarthritis or polyarthritis,
we determined whether they initiatedMTXmonotherapy
within 6 months after their diagnosis of PsA and baseline
visit and if they continuously used MTX monotherapy,
used it intermittently (interruption of more than 2
weeks), had another DMARD added or switched to
a different DMARD in the first year after diagnosis. We
defined responders as those with low disease activity at 6
and 12months.We defined non-responders as all patients
that had to switch after 3 months to another DMARD or if
another DMARD was added after 3 months and those
with high disease activity at 6 months. Low disease activity
was defined according to EULAR definition (not having
one tender and swollen joint),1 Disease Activity index for
PSoriatic Arthritis Low Disease Activity (DAPSA-LDA
(SJC66+ TJC68+ VAS Global (cm) + VAS Pain (cm) +
CRP ≤14), and MDA (5/7 remission criteria: SJC ≤1, TJC
≤1, LEI ≤1, PASI ≤1, patient global VAS ≤20 mm, patient
pain VAS ≤15 mm and HAQ ≤0.5).14 Conversely, those
who did not have low disease activity in these different
definitions were considered to have high disease activity.
Multiplex cytokine assay
The serum concentrations of several cytokines were
determined by a bead-based immunoassay (LEGENDplex
(BioLegend, San Diego, USA)) according to manufac-
turer’s protocol in the serum of selected responders and
non-responders to MTX at T0, T3 and T6 (ie, at time of
diagnosis and 3 and 6 months after diagnosis). All sam-
ples were analysed on the same day to avoid inter-assay
variation. We designed a custom panel of cytokines
related to disease pathophysiology,15–19 or based on exist-
ing evidence of involvement in response to MTX
therapy.20–25 This panel included interferon gamma
(IFNᵧ), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), TNFɑ, interleukin (IL) 9, IL-10, IL-17A,
IL-17F, chemokine C-C motif ligand 20 (CCL20), IL-23,
IL-22, IL-33 and ular endothelial growth factor (VEGF).
Online supplementary table 1 shows the minimal detect-
able concentration (MDC) of our assay per cytokine and
which bead was used for the detection. We defined defi-
nite MTX responders as patients who reached MDA at 6
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and 12 months or fulfilled both MDA joints criteria at 6
and 12 months on MTX monotherapy, without the need
for steroid injections. We defined definite non-
responders as patients who were not using MTX mono-
therapy continuously or were neither in MDA or EULAR
definition of low disease activity at 6 months.
Statistical analysis
We compared baseline characteristics in patients switching
and patients continuing MTX monotherapy using χ2 tests,
Fisher’s exact tests, t-tests and Wilcoxon rank-sum tests as
appropriate. LEGENDplex data analysis software (Vigene-
Tech, Évreux, France) and protocol for data analysis were
used to determine the concentration of the cytokines in
each sample. To analyse the dynamics of the cytokines over
time,marginal effectsmodels were used to compare respon-
ders to non-responders. The optimal correlation structure
was chosen based on the Akaike information criterion,
a statistic relating good fit (ie, likelihood) to complexity of
the model (ie, the number of parameters).26 For outcomes
below the detection limit, the detection limit was chosen as
value. Sensitivity analyses using 0 and half the detection
limit were performed. Heatmap and associated hierarchical
clustering of cytokines was generated using R and the
R package heatmap.2 (gplots).27 28
RESULTS
Of 219 patients with a phenotype of oligoarthritis or
polyarthritis at time of diagnosis, 183 (84%) started with
MTX monotherapy within 6 months of their diagnosis.
Table 1 shows the baseline characteristics of patients
starting on MTX monotherapy and those who did not.
Fifty-one patients with a definition of oligoarthritis or
polyarthritis at time of diagnosis have been excluded
because they did not have at least 1 year follow-up (27
stopped participating, 8 were lost to follow-up, 4 moved, 5
missed their T12 visit, 7 unknown).
Of the 183 patients starting on MTX monotherapy
within 6 months, 90 (49%) continued on MTX mono-
therapy until 12 months after diagnosis. Of the other
93 (51%) patients, 23 used MTX intermittently, 25
switched to a different DMARD (17 because of side-
effects, 7 because of insufficient effect, 1 unknown),
and in 45 patients, another DMARD was added
(online supplementary figure 1). Table 2 shows the
baseline characteristics of all patients who did not take
MTX continuously and all patients who remained on
MTX monotherapy over the 12-month follow-up per-
iod. Only the HAQ score significantly differed at base-
line between those two groups.
Reaching sustained MDA with MTX monotherapy
Figure 1A shows the 90 patients continuing MTX mono-
therapy until 12months meeting the different low disease
activity scores. Compared to the other disease activity
measures, a lower number of patients of 44 (49%, 24%
of total) reached MDA at 6 months. Of these 44 patients,
11 lost theirMDA status at 9 or 12months, and 33 patients
reached sustained MDA status for the first year after
diagnosis on MTX monotherapy (18% of total). Figure
1B shows which criteria of MDA were met or not by the
two different groups. Most patients not in MDA at 6
months did not meet the patient-related outcome mea-
sures included in the MDA criteria.
Longitudinal dynamics of cytokine profiles in the serum of
responders and non-responders to MTX monotherapy
For the analysis of longitudinal dynamics of cytokine pro-
files, we selected 32 definite non-responders (ie, 83
Table 1 Baseline characteristics of all patients and divided















Age (years) 53±14 53±14 51±16
Male (%) 110 (50) 93 (51) 17 (47)





10 (4–29) 10 (4–27) 6.4 (4.1–84)
Baseline disease scores
Oligoarthritis (%) 134 (61) 108 (59) 26 (72)
Polyarthritis (%) 85 (39) 75 (41) 10 (28)
Tender joint
count
5 (2–10) 5 (2–10) 4 (2–10)
Swollen joint
count
3 (2–6) 4 (2–6) 2 (1–4.5)
Elevated CRP
>10 mg/L
67 (37) 61 (40) 6 (20)
PASI 2.4 (0.6–4.6) 2.5 (0.7–4.7) 1.3 (0.4–4.5)
Pain VAS 48±27 49±26 47±31
Global VAS 47±25 48±25 39±28
LEI >0 (%) 82 (39) 70 (38) 15 (42)
Dactylitis (%) 35 (16) 32 (17) 3 (8)
HAQ total score 0.8 (0.4–1.1) 0.8 (0.4–1.0) 0.6 (0.3–1.1)
Medication






Results shown as mean±SD, n (%) or median (IQR). Baseline clinical
data of onepatientmissing,questionnaires of five patients aremissing.
BMI, body mass index; CRP C reactive protein; HAQ, Health
Assessment Questionnaire; LEI, Leeds Enthesitis Index; MTX,
methotrexate; PASI, Psoriasis Area and Severity Index; VAS, Visual
Analogue Scale.
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patients who switched to or added another DMARD after
T3 or did not reach MDA and no EULAR remission at T6,
minus 28 who switched before T3, minus 5 stopping
because of side effects, minus 18 (missing samples)) and
27 definite responders to MTX monotherapy (ie, 48 sus-
tained MDA or sustained joint-criteria, minus 11 patients
having had steroid injections and minus 10 patients (miss-
ing samples))(see also online supplementary figure 1). At
baseline, we found significant higher concentrations of
several cytokines in non-responders versus responders,
respectively: IL-23 (mean 62.94±25.02 vs 17.44±4.78,
p<0.05), TNFα (mean 7.83±2.79 vs 2.63±0.66, p<0.05),
GM-CSF (mean 6.5±2.07 vs 2.78±0.64, p<0.05), IFNγ
(mean 19.74±6.85 vs 6.67±1.29, p<0.05) and IL-10 (mean
2.08±0.6 vs 1.03±0.13, p<0.05) (figure 2A). In a marginal
model analysis, the course of IL-23 and IL-10 over 6months
remained significantly different between responders and
non-responders. Figure 2B displays a heatmap of the cyto-
kine profiles in the individual patients. The dendogram
shows that IL-23 clusters away from all other cytokines and
separates best responders and non-responders to MTX
monotherapy at baseline. Clinically, the definite non-
responders had at baseline a significantly higher TJC,
higher pain VAS, higher global VAS, higher HAQ score,
but lower enthesitis score (table 3).
DISCUSSION
We studied MTX use and response in an observational
usual care cohort of patients newly diagnosed with PsA.
Half of the patients (49%) who initially presented with
oligoarthritis or polyarthritis continued MTX monother-
apy until 12 months of follow-up. Only 33 patients of the
183 patients who started on MTX monotherapy (18%)
achieved sustained MDA after the first year with MTX
monotherapy. We found that non-responders to MTX
monotherapy, that is, patients switching to other/addi-
tional therapy or not in MDA or EULAR definition of
low disease activity at 6 months, had significantly higher
baseline concentrations of IL-23, TNFα, GM-CSF, IFN-γ
and IL-10.
Our study is the first to assess survival of and response
to MTX in usual care, within the first year after diagno-
sis. Our data reflect daily clinical practice, both concern-
ing the type of patients and the treatment chosen.
Treatment was not given in a treat-to-target regimen,
such as in the TICOPA study. In the TICOPA study,5
22.4% of patients reached MDA at 12 weeks. Further
analysis of efficacy of MTX monotherapy was not possi-
ble after 3 months, as treatment was escalated in the
tight control group. Other randomised controlled trials
including MTX monotherapy as a control group have
found comparable outcomes,6 7 respectively 29% reach-
ing MDA after 22 weeks, and 22.9% after 24 weeks and
the slightly higher 35.7% after 48 weeks. However, the
control-arms in these trials of MTXmonotherapy do not
reflect usual care, as treatment was escalated in many
patients and not all patients with PsA were eligible to
participate. In another observational cohort including
175 patients with PsA starting on MTX monotherapy for
the first time,8 only 17.4% of these patients reached MDA
at 6 months. However, these patients were not newly
diagnosed and patients with concomitant use of other
DMARDs were not excluded from this analysis. We stu-
died the survival of MTX in usual care patients and found
that 24% was in MDA at 6 months. Disease activity at 6
months was lower according to the less strict definitions of
disease activity, that is, the DAPSA-LDA, and EULAR
definition. Only 18% could maintain their MDA status
up until 1 year after diagnosis, which shows that reaching
sustained MDA within the first year after diagnosis on
MTX monotherapy is difficult in many newly diagnosed
patients with PsA.
Furthermore, our study aimed to screen for easy-to-
measure therapy-response biomarkers to aid clinicians
in recognising patients that will not respond to MTX
monotherapy. We used a sensitive bead-based immunoas-
say to simultaneously determine concentrations of the 12
cytokines. We found that non-responders to MTX, that is,
patients switching to other/additional therapy or not in
MDA or EULAR definition of low disease activity at
6 months, had significantly higher baseline concentra-
tions of IL-23, TNFα, GM-CSF, IFNγ and IL-10. Further-
more, our results show that IL-23 was high before, and was
Table 2 Baseline characteristics of patients who continued









Age (years) 52±13 54±14




4 (2–7) 3 (2–6)
Tender joint
count
6 (3–10) 4 (2–9)
Oligoarthritis
(%)
58 (62) 50 (56)
Polyarthritis (%) 35 (38) 40 (44)
PASI 2.6 (0.8–4.9) 2.4 (0.6–4.5)
Pain VAS 51±24 46±26
Global VAS 51±27 46±25
LEI >0 (%) 33 (37) 36 (39)
HAQ total score 0.8 (0.6–1.3)* 0.6 (0.3–0.9)
DAPSA 22.7±10.3 20.4±10.6
MDA (%) 2 (2) 6 (7)
Results shown as mean±SD, n (%) or median (IQR). Baseline clinical
data of one patient missing, questionnaires of three patients missing.
*p<0.05.
DAPSA, Disease Activity index for PSoriatic Arthritis; HAQ, Health
Assessment Questionnaire; LEI, Leeds Enthesitis Index; MDA,
minimal disease activity; MTX, methotrexate; PASI, Psoriasis Area
and Severity Index; VAS, Visual Analogue Scale.
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not effectively decreased during MTX monotherapy, in
the serum of patients not responding to MTX monother-
apy. In additional analysis, IL-23 showed to be the best
cytokine to differentiate between responders and non-
responders to MTX. However, this does depend on this
analysis on the higher detectable levels in the serum. Our
results correspond with other studies in other diseases
treated with MTX monotherapy, such as juvenile idio-
pathic arthritis, rheumatoid arthritis (RA) or psoriasis,
which also found a pre-existent higher concentration of
TNFα in non-responders,20 or lack of effect of MTX
monotherapy on IL-23 or IL-17 serum or plasma
concentrations.29 30 Together, this may explain why
MTX is not effective in patients with PsA with primarily
IL-23-driven disease. Surprisingly, we also found consis-
tently higher serum levels of the anti-inflammatory cyto-
kine IL-10 in our non-responders. In RA, IL-10-producing
T cells were found to be increased in MTX responders
corresponding with the historically viewed anti-
inflammatory capacities of IL-10.31 32 Our conflicting
results might reflect a feedback mechanism of IL-10 in
controlling severe disease. However, we found only low
levels of IL-10, which might not be biologically relevant.
Not only proinflammatory cytokines were higher at
baseline in non-responders than in responders to MTX
monotherapy; non-responders also clinically showed
higher disease activity, based mainly on the patient-
reported measures. Our study shows that IL-23 serum
levels can both objectively reflect patient-reported mea-
sures and MTX response, making it an interesting ther-
apy-response biomarker.
This study has several strengths and limitations. First, it
includes all patients with a new diagnosis of PsA and both
the population and the treatment strategy reflect current
usual care. It is suitable to describe MTX survival rates in
usual care. Drawing conclusions about the effect of MTX
should be done with caution, as there could be confound-
ing by indication. Therefore, we chose to display the
response on MTX as a percentage of the whole popula-
tion who started on MTX monotherapy. Second, we used
a sensitive assay to compare cytokine profiles in respon-
ders and non-responders, not only at baseline but also















































































































































Figure 1 (A) Different bars show the 90 patients using MTX monotherapy continuously in the first year of diagnosis with active
disease and low disease activity according to MDA criteria, DAPSA or EULAR definition at 6 months. (B) Graphs show the number
of patients that met theMDA criteria included patients in MDA and those that are not in MDA at 6 months. DAPSA, Disease Activity
index for PSoriatic Arthritis; MDA, minimal disease activity; MTX, methotrexate.
Psoriatic arthritis
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Figure 2 (A) Differences between serum concentrations of 12 cytokines in responders and non-responders analysed using
marginal effects models. Non-responders: patients who were not continuously using MTX or were neither in MDA or EULAR
definition of low disease activity at 6 months. Responders: patients who reachedMDA and EULAR definition of low disease activity
at 6 and 12 months on MTX monotherapy. Mean±SD, *p<0.05. (B) Heatmap depicts log2-transformed normalised expression of
cytokines (rows) for individual responders and non-responders (columns). Colour code for normalised expression of the cytokines
is provided in the key. MDA, minimal disease activity; MTX, methotrexate.
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after 3 and 6 months of MTX therapy to investigate the
effect of therapy on all these cytokines. However, we will
need to validate the use of serum IL-23 as a therapy-
response biomarker in future studies.
In conclusion, our results show that only 18% of
patients with PsA achieve sustained MDA with MTX
monotherapy after 1 year. Non-responders show worse
patient-reported outcome measures and have higher IL-
23 serum levels at baseline. This study highlights the
potential value of use of new tools, such as measuring
cytokine profiles, to stratify patients for underlying driv-
ing pathogenic mechanisms of their disease. Subse-
quently, rheumatologists can use this to personalise
therapy choices, not only for MTX, in PsA to improve
patient outcomes.
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Table 3 Difference in clinical characteristics of responders







Age (years) 52±14 53±14
Male (%) 20 (63) 17 (63)
Baseline disease scores
Swollen joint count 5 (3–8) 3 (2–5)
Tender joint count 6 (3–10) 4 (2–7)*
PASI 2.6 (1.1–6.5) 1.8 (0.4–3.6)
Pain VAS 54±24 40±30*
Global VAS 57±28 40±24*
LEI >0 (%) 9 (28) 14 (54)*
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